Organon: ‘Those $4bn-$5bn Biologics – That’s A Nice Place To Play In Biosimilars’
No Plans To Manufacture, Allocating Capital For Partnerships, Company Tells Generics Bulletin
Joe Azzinaro, Organon’s global commercial leader for biosimilars, sat down to talk with Generics Bulletin about its commercialization expertise and investments for the future.
